Business Description
Allarity Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US0167443029
Description
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.13 | |||||
| Equity-to-Asset | -0.23 | |||||
| Debt-to-Equity | -0.47 | |||||
| Debt-to-EBITDA | -0.12 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 51.8 | |||||
| 3-Year EPS without NRI Growth Rate | 44.8 | |||||
| 3-Year FCF Growth Rate | 52.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 12.72 | |||||
| 9-Day RSI | 12.74 | |||||
| 14-Day RSI | 13.76 | |||||
| 6-1 Month Momentum % | -56.37 | |||||
| 12-1 Month Momentum % | -98.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.14 | |||||
| Quick Ratio | 0.14 | |||||
| Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -266.1 | |||||
| Shareholder Yield % | -9.75 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -89.6 | |||||
| ROIC % | -124.75 | |||||
| ROC (Joel Greenblatt) % | -44566.93 | |||||
| ROCE % | -5549.02 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.43 | |||||
| EV-to-EBITDA | -0.43 | |||||
| EV-to-FCF | -0.38 | |||||
| Earnings Yield (Greenblatt) % | -232.56 | |||||
| FCF Yield % | -727.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALLR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Allarity Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2836.18 | ||
| Beta | 0 | ||
| Volatility % | 85.05 | ||
| 14-Day RSI | 13.76 | ||
| 14-Day ATR ($) | 0.581342 | ||
| 20-Day SMA ($) | 1.6789 | ||
| 12-1 Month Momentum % | -98.63 | ||
| 52-Week Range ($) | 0.9 - 366.4 | ||
| Shares Outstanding (Mil) | 1.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Allarity Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Allarity Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Allarity Therapeutics Inc Frequently Asked Questions
What is Allarity Therapeutics Inc(ALLR)'s stock price today?
The current price of ALLR is $0.90. The 52 week high of ALLR is $366.40 and 52 week low is $0.90.
When is next earnings date of Allarity Therapeutics Inc(ALLR)?
The next earnings date of Allarity Therapeutics Inc(ALLR) is 2024-05-10 Est..
Does Allarity Therapeutics Inc(ALLR) pay dividends? If so, how much?
Allarity Therapeutics Inc(ALLR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers